Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain.
María PresaDavid VicenteAntonio CallesLaura Salinas-OrtegaJaesh NaikLuis F GarcíaJavier SotoPublished in: ClinicoEconomics and outcomes research : CEOR (2023)
The results of this study suggest that lorlatinib may be a dominant treatment option versus alectinib. Considering a willingness-to-pay threshold of €25,000/QALY, lorlatinib may be an efficient option compared to brigatinib.